Open AccessS103: EFFICACY AND SAFETY OF ARI0002H, AN ACADEMIC BCMA‐DIRECTED CAR‐T CELL THERAPY WITH FRACTIONATED INITIAL THERAPY AND BOOSTER DOSE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
Author(s) -
Fernandez De Larrea C.,
GonzálezCalle V.,
OliverCaldés A.,
Cabañas V.,
RodríguezOtero P.,
EspañolRego M.,
Reguera J. L.,
LópezCorral L.,
MartinAntonio B.,
Paiva B.,
Inogés S.,
Rosiñol L.,
LópezDíaz de Cerio A.,
Tovar N.,
LópezParra M.,
RodríguezLobato L. G.,
SánchezSalinas A.,
Varea S.,
OrtizMaldonado V.,
Pérez Simón J. A.,
Prósper F.,
Juan M.,
Moraleda J. M.,
Mateos M. V.,
Pascal M.,
UrbanoIspizua A.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000843308.71619.a0
Subject(s) - medicine , fludarabine , cytokine release syndrome , lenalidomide , multiple myeloma , cyclophosphamide , oncology , regimen , bortezomib , adverse effect , pharmacology , gastroenterology , chemotherapy , immunotherapy , cancer , chimeric antigen receptor